ICU Medical Inc
NASDAQ:ICUI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
84.39
183.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ICU Medical Inc
ICU Medical Inc
Cost of Revenue
ICU Medical Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-26%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cost of Revenue
-$625.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$527.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-11%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cost of Revenue
-$705m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
ICU Medical Inc
Glance View
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 8,500 full-time employees. The firm provides infusion systems, infusion consumables and critical care products used in hospital, alternate site and home care settings. The firm's product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle free connectors. Its oncology products include ChemoLock and ChemoClave. Its IV consumables include Clave IV Connector Technology, IV Sets, Peripheral IV Catheters and Disinfecting Caps. Its primary critical care products include Cogent, CardioFlo, TDQ and OptiQ, TriOx, Transpac and SafeSet. Its IV Solutions products include IV Therapy and Diluents, and Irrigation. Its Infusion System products include Infusion Pump Hardware, IV Mediation Safety Software and Professional Services. The company offers blood pressure monitoring system.
See Also
What is ICU Medical Inc's Cost of Revenue?
Cost of Revenue
-1.6B
USD
Based on the financial report for Sep 30, 2024, ICU Medical Inc's Cost of Revenue amounts to -1.6B USD.
What is ICU Medical Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-26%
Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for ICU Medical Inc have been -25% over the past three years , -14% over the past five years , and -26% over the past ten years .
You don't have any saved screeners yet
